To the full analysis
Buyback calculator for Silence Therapeutics
Silence Therapeutics stock: key metrics
SLNSilence Therapeutics had an operating margin of −16,056% and a return on invested capital (ROIC) of −53.3% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 100.0% | −219.2% | −196.5% |
| 2007 | −19.7% | −143.0% | −126.2% |
| 2008 | −203.8% | −352.7% | −336.6% |
| 2009 | −194.4% | −438.4% | −433.6% |
| 2010 | −146.0% | −365.9% | −371.7% |
| 2011 | −370.3% | −803.5% | −796.7% |
| 2012 | −1,972.4% | −3,575.5% | −16,125.2% |
| 2013 | −4,727.4% | −7,753.8% | −7,694.0% |
| 2014 | −59,126.7% | −80,846.7% | −73,920.0% |
| 2015 | no data | no data | no data |
| 2016 | −1,031.3% | −1,546.2% | −1,096.1% |
| 2017 | −49,543.8% | −89,943.8% | −10,112.5% |
| 2018 | no data | no data | no data |
| 2019 | 100.0% | −9,317.2% | −8,025.4% |
| 2020 | 31.3% | −654.3% | −594.0% |
| 2021 | 39.9% | −369.0% | −317.4% |
| 2022 | 37.8% | −281.9% | −232.4% |
| 2023 | 59.3% | −195.5% | −170.5% |
| 2024 | 72.7% | −146.4% | −104.7% |
| 2025 | 61.5% | −16,056.0% | −15,851.9% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −24.4% | −49.0% | −22.8% |
| 2007 | −28.9% | −63.6% | −26.2% |
| 2008 | −55.3% | −70.0% | −51.7% |
| 2009 | −84.0% | −66.8% | −68.0% |
| 2010 | −27.3% | −37.5% | −25.9% |
| 2011 | −17.8% | −16.0% | −17.2% |
| 2012 | −100.0% | −25.8% | −100.0% |
| 2013 | −32.6% | −32.8% | −30.7% |
| 2014 | −39.9% | −34.6% | −37.2% |
| 2015 | −11.0% | −17.5% | −10.8% |
| 2016 | −15.6% | −79.4% | −15.1% |
| 2017 | −3.1% | −93.0% | −2.9% |
| 2018 | −52.5% | −37.2% | −47.3% |
| 2019 | −93.7% | −50.3% | −42.5% |
| 2020 | −100.0% | −58.5% | −37.9% |
| 2021 | −100.0% | −51.2% | −41.0% |
| 2022 | −100.0% | −47.2% | −38.2% |
| 2023 | −100.0% | −48.3% | −45.8% |
| 2024 | −42.3% | −44.4% | −28.0% |
| 2025 | −100.0% | −53.3% | −67.4% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.